AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11796602 — intervention group
Group type: EXPERIMENTAL
Intervention: Group receiving extra vaccine dose
Number of subjects: 42
Study 10643695 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment with >50% improvement after 1 year
Number of subjects: 271
Study 10643695 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment with 20-50% improvement after 1 year
Number of subjects: 271
Study 10643695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group of patients with >50% and 20-50% improvement
Number of subjects: 271
Study 10643695 — intervention group
Group type: COMPARATOR
Intervention: Patients without improvement after 1 year
Number of subjects: 271
Study 10643695 — intervention group
Group type: COMPARATOR
Intervention: Patients who discontinued methotrexate treatment during the first year
Number of subjects: 271
Study 9007423 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration of a to-scale computer simulation of a real multi-storey building
Number of subjects: 10
Study 9007423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exploration of the real building or computer simulation)
Number of subjects: 10
Study 1380432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 10mg intravenously before and after cisplatin infusion
Number of subjects: 54
Study 1380432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5mg intravenously 15 minutes before cisplatin
Number of subjects: 54
Study 1380432 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 2 mg/kg plus lorazepam administered 15 minutes before cisplatin
Number of subjects: 54
Study 6092288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day
Number of subjects: 45
Study 6092288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/day
Number of subjects: 45
Study 6092288 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid 60 ml/day
Number of subjects: 45
Study 6092288 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 45
Study 30844687 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (200 μg daily)
Number of subjects: 47
Study 30844687 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D (4000 IU daily)
Number of subjects: 47
Study 28911155 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein acetyls (GlycA)
Number of subjects: 8749
Study 28911155 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin‐1 receptor antagonist (IL‐1RA)
Number of subjects: 8749
Study 28911155 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐sensitivity C‐reactive protein (hs‐CRP)
Number of subjects: 8749
Study 25443268 — intervention group
Group type: EXPERIMENTAL
Intervention: mp‐MRI/biopsy
Number of subjects: 1140
Study 25443268 — intervention group
Group type: COMPARATOR
Intervention: TRUS-guided biopsy
Number of subjects: 1140
Study 23326188 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid alone (66 mg)
Number of subjects: 62
Study 23326188 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (49.5 mg) plus diclofenac sodium (5 mg)
Number of subjects: 62
Study 23326188 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (49.5 mg) plus sodium clodronate (5 mg)
Number of subjects: 62
Study 23326188 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 62
Study 21233227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI) in children with SCI
Number of subjects: 10
Study 21233227 — intervention group
Group type: COMPARATOR
Intervention: Diffusion Tensor Imaging (DTI) in healthy controls
Number of subjects: 10
Study 21233227 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of DTI indices with ISNCSCI scores in children with SCI
Number of subjects: 10
Study 17614029 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of prednisolone (Pred)
Number of subjects: 9
Study 17614029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 9
Study 16931511 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPSN mutations R164C and L283P
Number of subjects: 2
Study 16931511 — intervention group
Group type: COMPARATOR
Intervention: Wild-type AChR subunits
Number of subjects: 2
Study 12950862 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isoflurane
Number of subjects: 25
Study 12950862 — intervention group
Group type: COMPARATOR
Intervention: Intravenous remifentanil
Number of subjects: 25
Study 12950862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (isoflurane and remifentanil)
Number of subjects: 25
Study 11020675 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual in-line stabilization
Number of subjects: 14
Study 11020675 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller straight blade
Number of subjects: 14
Study 11020675 — intervention group
Group type: COMPARATOR
Intervention: Cervical collar immobilization
Number of subjects: 14
Study 11020675 — intervention group
Group type: COMPARATOR
Intervention: Macintosh curved blade and Corazelli-London-McCoy hinged blade
Number of subjects: 14
Study 9116411 — intervention group
Group type: EXPERIMENTAL
Intervention: Body surface trigger
Number of subjects: 12
Study 9116411 — intervention group
Group type: COMPARATOR
Intervention: Airway trigger
Number of subjects: 12
Study 8505826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation starting on the second to fourth day of life; 2000 IU intramuscularly three times a week starting on the 10th to 14th day of life, followed by 2500 IU/d orally when enteral feedings reached 60 kcal/kg per day.
Number of subjects: 48
Study 8505826 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A supplementation starting on the 10th to 14th day of life; 2000 IU intramuscularly three times a week, followed by 2500 IU/d orally when enteral feedings reached 60 kcal/kg per day.
Number of subjects: 48
Study 8505826 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 48
Study 3087801 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (TRF) 60 mg b.i.d. for 7 days
Number of subjects: 141
Study 3087801 — intervention group
Group type: COMPARATOR
Intervention: Mequitazine (MQZ) 5 mg b.i.d. for 7 days
Number of subjects: 141
Study 3087801 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (TRF)
Number of subjects: 141
Study 3087801 — intervention group
Group type: COMPARATOR
Intervention: Mequitazine (MQZ)
Number of subjects: 141
Study 2819021 — intervention group
Group type: EXPERIMENTAL
Intervention: Skimmed milk
Number of subjects: 10
Study 2819021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-enriched skimmed milk
Number of subjects: 10
Study 2819021 — intervention group
Group type: EXPERIMENTAL
Intervention: Watercress soup
Number of subjects: 10
Study 2819021 — intervention group
Group type: COMPARATOR
Intervention: Ca-enriched milk (1 pint daily for 4 weeks)
Number of subjects: 10
Study 29226958 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual masking exposure (VBE) to masked spiders
Number of subjects: 60
Study 29226958 — intervention group
Group type: COMPARATOR
Intervention: Control exposure to masked flowers
Number of subjects: 60
Study 29226958 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearly visible exposure to spider images
Number of subjects: 60
Study 29226958 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual masking exposure (VBE)
Number of subjects: 60
Study 28911092 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent ovarian function suppression (OFS) with chemotherapy using triptorelin
Number of subjects: 1872
Study 28911092 — intervention group
Group type: COMPARATOR
Intervention: Sequential OFS post-chemotherapy using triptorelin
Number of subjects: 1872
Study 28911092 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent OFS with chemotherapy in women <40 years at diagnosis
Number of subjects: 1872
Study 28911092 — intervention group
Group type: COMPARATOR
Intervention: Sequential OFS post-chemotherapy in women <40 years at diagnosis
Number of subjects: 1872
Study 26258561 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring parenting practice
Number of subjects: 301
Study 26258561 — intervention group
Group type: EXPERIMENTAL
Intervention: Limit setting of soda/snacks (SS)
Number of subjects: 301
Study 26258561 — intervention group
Group type: EXPERIMENTAL
Intervention: Limit setting of screen media (SM)
Number of subjects: 301
Study 26258561 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 301
Study 23458591 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 (0.25 mg twice daily, 1 mg four times daily, and 0.5 mg/1 mg twice daily)
Number of subjects: 0
Study 23458591 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg twice daily)
Number of subjects: 0
Study 23458591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20579848 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy (∼ 1300 mg/d of calcium from dairy products)
Number of subjects: 30
Study 20579848 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium (∼ 1300 mg/d of calcium; ∼ 700 mg/d from diet and 600 mg/d from a supplement)
Number of subjects: 30
Study 20579848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19049544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS applied to the left and right dlPFC
Number of subjects: 24
Study 19049544 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control condition)
Number of subjects: 24
Study 16503524 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 71
Study 16503524 — intervention group
Group type: COMPARATOR
Intervention: Control (routine intravenous oxytocin infusion)
Number of subjects: 71
Study 15055095 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Hatha yoga intervention (1 hour, twice a week for 6 weeks)
Number of subjects: 22
Study 15055095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment during observation period)
Number of subjects: 22
Study 11816532 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and progestin (E + P), n = 122
Number of subjects: 172
Study 11816532 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone (E), n = 50
Number of subjects: 172
Study 9406364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 66
Study 9406364 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine and dexamethasone
Number of subjects: 66
Study 8481745 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Strategy Enhancement (CSE)
Number of subjects: 49
Study 8481745 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving (PS)
Number of subjects: 49
Study 8481745 — intervention group
Group type: COMPARATOR
Intervention: Waiting period (Control)
Number of subjects: 49
Study 3320259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase therapy
Number of subjects: 173
Study 3320259 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 173
Study 31596774 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-centered video counseling (PEER)
Number of subjects: 0
Study 31596774 — intervention group
Group type: COMPARATOR
Intervention: Standard physician video counseling (PHYS)
Number of subjects: 0
Study 31596774 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PEER and PHYS
Number of subjects: 0
Study 30177236 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexanolone 60 μg/kg per h (BRX60)
Number of subjects: 246
Study 30177236 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexanolone 90 μg/kg per h (BRX90)
Number of subjects: 246
Study 30177236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 27046747 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D laparoscopy (Group B, n = 42)
Number of subjects: 90
Study 27046747 — intervention group
Group type: COMPARATOR
Intervention: 2-D laparoscopy (Group A, n = 48)
Number of subjects: 90
Study 27046747 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D laparoscopy (Group B)
Number of subjects: 90
Study 27046747 — intervention group
Group type: COMPARATOR
Intervention: 2-D laparoscopy (Group A)
Number of subjects: 90
Study 23681501 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.1 mmol/kg
Number of subjects: 229
Study 23681501 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.3 mmol/kg
Number of subjects: 229
Study 23681501 — intervention group
Group type: COMPARATOR
Intervention: Gadobutrol 0.03 mmol/kg
Number of subjects: 229
Study 23681501 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (all doses)
Number of subjects: 229
Study 22595446 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable metal stent (SEMS)
Number of subjects: 108
Study 22595446 — intervention group
Group type: COMPARATOR
Intervention: Plastic stent (PS)
Number of subjects: 108
Study 20133200 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH only with GnRH antagonist
Number of subjects: 750
Study 20133200 — intervention group
Group type: COMPARATOR
Intervention: P25 subset on stimulation days 1, 5, or 8
Number of subjects: 750
Study 18226768 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy plus cardiac resynchronization therapy (CRT)
Number of subjects: 405
Study 18226768 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OPT)
Number of subjects: 405
Study 16427528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine IV before surgical incision, followed by normal saline infusion and normal saline IV at wound closure (Group 1)
Number of subjects: 45
Study 16427528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine IV before surgery, followed by ketamine infusion 600 mug . kg(‐1) . h(‐1) until wound closure (Group 2)
Number of subjects: 45
Study 16427528 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline IV before surgery, followed by saline infusion and then 0.5 mg/kg ketamine IV at wound closure (Group 3)
Number of subjects: 45
Study 12714526 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT)
Number of subjects: 734
Study 12714526 — intervention group
Group type: COMPARATOR
Intervention: Autologous stem cell transplantation (auto-SCT)
Number of subjects: 734
Study 11250629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 108
Study 11250629 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 108
Study 9054083 — intervention group
Group type: EXPERIMENTAL
Intervention: Klean‐Prep
Number of subjects: 104
Study 9054083 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparation
Number of subjects: 104
Study 8307847 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.2 mg/kg iv)
Number of subjects: 19
Study 8307847 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg iv)
Number of subjects: 19
Study 8307847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 19
Study 8307847 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol or Atropine
Number of subjects: 19
Study 3554131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 55) received a three-part individualized course in child safety.
Number of subjects: 171
Study 3554131 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 54) received routine safety education.
Number of subjects: 171
Study 3554131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 55) for hazard score assessment.
Number of subjects: 171
Study 3554131 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 54) for hazard score assessment.
Number of subjects: 171
Study 3554131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups reported accidents.
Number of subjects: 171
Study 31100535 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlebe (internet-based cognitive behavior therapy) for 5 months
Number of subjects: 32
Study 31100535 — intervention group
Group type: COMPARATOR
Intervention: Basic speech-restructuring training (control group)
Number of subjects: 32
Study 27524365 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 727
Study 27524365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 727
Study 27524365 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 727
Study 27524365 — intervention group
Group type: COMPARATOR
Intervention: Control (Citalopram)
Number of subjects: 727
Study 24907137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric aquatic therapy
Number of subjects: 24
Study 24907137 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 22887778 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 35% comfrey root extract plus 1.2% methyl nicotinate
Number of subjects: 379
Study 22887778 — intervention group
Group type: COMPARATOR
Intervention: Methyl nicotinate
Number of subjects: 379
Study 22887778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 20102347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg) injection
Number of subjects: 10
Study 19248200 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg once daily for 8 weeks)
Number of subjects: 274
Study 19248200 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg once daily for 8 weeks)
Number of subjects: 274
Study 19248200 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg once daily for 8 weeks)
Number of subjects: 274
Study 19248200 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole (40 mg once daily for 8 weeks)
Number of subjects: 274
Study 17602058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 17602058 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide plus dexamethasone
Number of subjects: 0
Study 17602058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 0
Study 17602058 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimens including thalidomide
Number of subjects: 0
Study 17602058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, thalidomide, lenalidomide, and other novel agents
Number of subjects: 0
Study 14767299 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for 4 years
Number of subjects: 3040
Study 14767299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study 11164694 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating voucher incentive schedule
Number of subjects: 80
Study 11164694 — intervention group
Group type: COMPARATOR
Intervention: Non-incentive schedule
Number of subjects: 80
Study 9569659 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinically depressed group
Number of subjects: 75
Study 9569659 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed control group
Number of subjects: 75
Study 8149503 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 1
Study 8149503 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent exercise
Number of subjects: 1
Study 8149503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 3170699 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 (mifepristone)
Number of subjects: 0
Study 3170699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31611264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 52
Study 29231474 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm acupuncture at Zhongwan (CV 12)
Number of subjects: 62
Study 29231474 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture (twirling reinforcing at Zhongwan (CV 12))
Number of subjects: 62
Study 25595138 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 39
Study 25595138 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day) + inhaled beclometasone (400 μg/day)
Number of subjects: 39
Study 25595138 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beclometasone (400 μg/day)
Number of subjects: 39
Study 25595138 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin + inhaled beclometasone
Number of subjects: 39
Study 24170120 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpendicular incision (group 2)
Number of subjects: 53
Study 24170120 — intervention group
Group type: COMPARATOR
Intervention: Parallel incision (group 1)
Number of subjects: 53
Study 24170120 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 21828967 — intervention group
Group type: COMPARATOR
Intervention: Control group (education only)
Number of subjects: 300
Study 21828967 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment applied to the nares twice daily
Number of subjects: 300
Study 21828967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin plus daily 4% chlorhexidine body washes
Number of subjects: 300
Study 21828967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin plus daily dilute bleach water baths
Number of subjects: 300
Study 20057901 — intervention group
Group type: EXPERIMENTAL
Intervention: Xience V everolimus-eluting stent
Number of subjects: 3
Study 17134636 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA supplementation (1 to 3.4 g/day) for 4 to 6 months
Number of subjects: 18
Study 15181294 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast advancement (30 ml/kg/day)
Number of subjects: 53
Study 15181294 — intervention group
Group type: COMPARATOR
Intervention: Slow advancement (15 ml/kg/day)
Number of subjects: 53
Study 15181294 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 53
Study 11275937 — intervention group
Group type: EXPERIMENTAL
Intervention: ioxaglate 320
Number of subjects: 2001
Study 11275937 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol 320
Number of subjects: 2001
Study 11275937 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol 340
Number of subjects: 2001
Study 9402453 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency catheter ablation
Number of subjects: 69